Emerging Treatments in C Difficile

December 16, 2021
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

Dr. Carl V. Crawford led a panel in discussing treatments in the pipeline for CDI.

A group of experts recently presented data and knowledge on the ongoing struggle to reduce the spread and treat clostridium difficile infections (CDI).

A team, led by Carl V. Crawford, MD, Weill Cornell Medicine, presented on Nov. 10 during the Institutional Perspectives in Infectious Diseases: Management of C. Difficile.

Joining Crawford were Andrea Betesh, MD, Harjot K Singh, MD, and Charlie Buffie, MD, PhD, all of Weill Cornell Medicine. The 4 experts discussed best treatment options for patients, understanding the disease, and what treatments and clinical trials are emerging in the field